Tafamidis Free Acid (NI)
Vyndamax are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Systematic Name
2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
Therapeutic Category
Transthyretin amyloidosis
Suitable Formulations
Solid
Approvals
US DMF
EU-WC